{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:58:23Z","timestamp":1785430703585,"version":"3.56.0"},"posted":{"date-parts":[[2025,8,25]]},"group-title":"Cancer Biology","reference-count":48,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"funder":[{"award":["RO1 CA 297845"],"award-info":[{"award-number":["RO1 CA 297845"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"award":["RO1 CA 271606"],"award-info":[{"award-number":["RO1 CA 271606"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  There remains an unmet clinical need for improved treatment strategies in Acute Myeloid Leukemia (AML). Although radiopharmaceutical therapies targeting non-cancer-selective antigens have shown promise in AML, their clinical utility is often limited by prolonged bone marrow suppression. Using a unique proteomics-based strategy, we recently identified the active conformation of integrin-\u03b22 (aITGB2) as a novel, tumor-selective target for AML. Importantly, this conformational epitope is expressed widely on AML cells but minimally on normal marrow progenitors\/healthy tissues. Here we first confirmed widespread aITGB2 expression on AML tumors that was largely independent of tumor genotype or prior therapeutic regimen. We developed diagnostic and therapeutic radiopharmaceuticals targeting aITGB2 utilizing a conformation-specific antibody (clone 7065). PET\/CT imaging with\n                  <jats:sup>89<\/jats:sup>\n                  Zr and\n                  <jats:sup>134<\/jats:sup>\n                  Ce-labeled 7065 in AML models revealed high target-mediated uptake, greater than that compared to standard of care [\n                  <jats:sup>18<\/jats:sup>\n                  F]-FDG. PET\/CT imaging with [\n                  <jats:sup>89<\/jats:sup>\n                  Zr]DFO*-7065 showed reduced binding to normal bone marrow and immune cells in humanized immune system mice compared to [\n                  <jats:sup>89<\/jats:sup>\n                  Zr]DFO*-anti-CD33. For therapy, we developed [\n                  <jats:sup>225<\/jats:sup>\n                  Ac]Macropa-PEG\n                  <jats:sub>4<\/jats:sub>\n                  -7065 using an optimized chelator-linker combination. Treatment with [\n                  <jats:sup>225<\/jats:sup>\n                  Ac]Macropa-PEG\n                  <jats:sub>4<\/jats:sub>\n                  -7065 in Nomo-1 and PDX AML disseminated models delayed tumor growth and improved overall survival compared to controls, including [\n                  <jats:sup>225<\/jats:sup>\n                  Ac]DOTA-anti-CD33, a clinical stage-radioimmunotherapy under evaluation in AML. Relapsed tumors demonstrated persistent aITGB2 expression, supporting continued development of fractionated dosing schemes, and proteomics analysis indicated activation of TCA cycle and carbon metabolism pathways, consistent with therapy-induced stress responses. These findings highlight [\n                  <jats:sup>89<\/jats:sup>\n                  Zr]DFO*-7065 and [\n                  <jats:sup>225<\/jats:sup>\n                  Ac]Macropa-7065 as a promising aITGB2-targeted theranostic pair with potential for imaging and treatment in future clinical translation.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>One Sentence Summary<\/jats:title>\n                  <jats:p>This study demonstrates promising preclinical efficacy of aITGB2-targeted radiotheranostics for selective imaging and therapy in AML.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.08.21.671206","type":"posted-content","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T05:25:19Z","timestamp":1756185919000},"source":"Crossref","is-referenced-by-count":0,"title":["Effective imaging and treatment of Acute Myeloid Leukemia with radiotheranostics targeting the activated conformation of integrin-\u03b2eta2"],"prefix":"10.64898","author":[{"given":"Anju","family":"Wadhwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kondapa Naidu","family":"Bobba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil P.","family":"Bidkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis","family":"Mayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"Rampersaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhilash","family":"Barpanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Prudhvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrik S.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Greenland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Balitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athira","family":"Raveendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhankar","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha","family":"Basak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corynn","family":"Kasap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juwita","family":"Huebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Lopez","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Steri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarret J.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachdev S.","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngho","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry F.","family":"VanBrocklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron C.","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7465-6964","authenticated-orcid":false,"given":"Arun P.","family":"Wiita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Flavell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025082810202021000_2025.08.21.671206v1.1","unstructured":"Key Statistics for Acute Myeloid Leukemia (AML) (available at https:\/\/www.cancer.org\/cancer\/types\/acute-myeloid-leukemia\/about\/key-statistics.html)."},{"key":"2025082810202021000_2025.08.21.671206v1.2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-019-0774-x","article-title":"Recent drug approvals for acute myeloid leukemia","volume":"12","year":"2019","journal-title":"Journal of Hematology & Oncology"},{"key":"2025082810202021000_2025.08.21.671206v1.3","doi-asserted-by":"crossref","unstructured":"G. W. Roloff , O. Odenike , A. Bajel , A. H. Wei , N. Foley , G. L. Uy , Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022. Am Soc Clin Oncol Educ Book, 568\u2013583 (2022).","DOI":"10.1200\/EDBK_349605"},{"key":"2025082810202021000_2025.08.21.671206v1.4","doi-asserted-by":"crossref","first-page":"101466","DOI":"10.1016\/j.beha.2023.101466","article-title":"Allogeneic hematopoietic cell transplantation in acute myeloid leukemia","volume":"36","year":"2023","journal-title":"Best Practice & Research Clinical Haematology"},{"key":"2025082810202021000_2025.08.21.671206v1.5","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.39"},{"key":"2025082810202021000_2025.08.21.671206v1.6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1158\/2643-3230.BCD-23-0258","article-title":"CD33\u2013CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells","volume":"6","year":"2025","journal-title":"Blood Cancer Discovery"},{"key":"2025082810202021000_2025.08.21.671206v1.7","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.3390\/cancers13215570","article-title":"Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials","volume":"13","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025082810202021000_2025.08.21.671206v1.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2025082810202021000_2025.08.21.671206v1.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025082810202021000_2025.08.21.671206v1.10","doi-asserted-by":"crossref","first-page":"101250","DOI":"10.1016\/j.blre.2024.101250","article-title":"Continuing progress in radioimmunotherapy for hematologic malignancies","volume":"69","year":"2025","journal-title":"Blood Reviews"},{"key":"2025082810202021000_2025.08.21.671206v1.11","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1078-0432.CCR-21-3712","article-title":"Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nano-Generator Actinium-225-Lintuzumab","volume":"28","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025082810202021000_2025.08.21.671206v1.12","first-page":"1128","article-title":"225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models","volume":"10","year":"2020","journal-title":"Cancer Med"},{"key":"2025082810202021000_2025.08.21.671206v1.13","first-page":"241340","article-title":"Safety and Dosimetric Analysis of Lintuzumab-Ac225 in Combination with Intensive CLAG-M Chemotherapy in Patients with Relapsed\/Refractory AML","volume":"65","year":"2024","journal-title":"Journal of Nuclear Medicine"},{"key":"2025082810202021000_2025.08.21.671206v1.14","unstructured":"Clinical Trial: NCT03441048 - My Cancer Genome (available at https:\/\/www.mycancergenome.org\/content\/clinical_trials\/NCT03441048\/)."},{"key":"2025082810202021000_2025.08.21.671206v1.15","unstructured":"First Clinical Trial of Actimab-A Triplet Combination to Begin in AML Blood Cancers Today (available at https:\/\/www.bloodcancerstoday.com\/post\/first-clinical-trial-of-actimab-a-triplet-combination-to-begin-in-aml)."},{"key":"2025082810202021000_2025.08.21.671206v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2014.04.001"},{"key":"2025082810202021000_2025.08.21.671206v1.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111951"},{"key":"2025082810202021000_2025.08.21.671206v1.18","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2060735"},{"key":"2025082810202021000_2025.08.21.671206v1.19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.229492"},{"key":"2025082810202021000_2025.08.21.671206v1.20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2317"},{"key":"2025082810202021000_2025.08.21.671206v1.21","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s43018-023-00652-6","article-title":"Structural surfaceomics reveals an AML-specific conformation of integrin \u03b22 as a CAR T cellular therapy target","volume":"4","year":"2023","journal-title":"Nat Cancer"},{"key":"2025082810202021000_2025.08.21.671206v1.22","doi-asserted-by":"crossref","first-page":"e937","DOI":"10.1097\/HS9.0000000000000937","article-title":"CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them","volume":"7","year":"2023","journal-title":"HemaSphere"},{"key":"2025082810202021000_2025.08.21.671206v1.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0201-9"},{"key":"2025082810202021000_2025.08.21.671206v1.24","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00259-016-3499-x","article-title":"Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025082810202021000_2025.08.21.671206v1.25","first-page":"694","article-title":"Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET","volume":"48","year":"2020","journal-title":"European journal of nuclear medicine and molecular imaging"},{"key":"2025082810202021000_2025.08.21.671206v1.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265355"},{"key":"2025082810202021000_2025.08.21.671206v1.27","doi-asserted-by":"publisher","DOI":"10.7150\/thno.92742"},{"key":"2025082810202021000_2025.08.21.671206v1.28","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201709532"},{"key":"2025082810202021000_2025.08.21.671206v1.29","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1200\/jco.2011.29.15_suppl.6516","article-title":"Phase I trial of the targeted alpha-particle nano-generator actinium-225 (225Ac-lintuzumab) (anti-CD33; HuM195) in acute myeloid leukemia (AML)","volume":"29","year":"2011","journal-title":"JCO"},{"key":"2025082810202021000_2025.08.21.671206v1.30","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.jmir.2019.11.118","article-title":"A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)","volume":"50","year":"2019","journal-title":"Journal of Medical Imaging and Radiation Sciences"},{"key":"2025082810202021000_2025.08.21.671206v1.31","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1182\/blood-2024-198004","article-title":"Targeting the Membrane-Proximal Domain of CD33 to Maximize the Efficacy of Natural Killer Cell-Based Immunotherapies","volume":"144","year":"2024","journal-title":"Blood"},{"key":"2025082810202021000_2025.08.21.671206v1.32","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0251"},{"key":"2025082810202021000_2025.08.21.671206v1.33","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/56\/3\/012"},{"key":"2025082810202021000_2025.08.21.671206v1.34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3724"},{"key":"2025082810202021000_2025.08.21.671206v1.35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/BS9.0000000000000140","article-title":"Immune therapy: a new therapy for acute myeloid leukemia","volume":"5","year":"2023","journal-title":"Blood Sci"},{"key":"2025082810202021000_2025.08.21.671206v1.36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1260470"},{"key":"2025082810202021000_2025.08.21.671206v1.37","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.3390\/cancers15102713","article-title":"The Black Hole: CAR T Cell Therapy in AML","volume":"15","year":"2023","journal-title":"Cancers (Basel"},{"key":"2025082810202021000_2025.08.21.671206v1.38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/17474086.2025.2449863","article-title":"Radioimmunotherapy of acute myeloid leukemia: a critical assessment of its prospects and limitations","volume":"18","year":"2025","journal-title":"Expert Rev Hematol"},{"key":"2025082810202021000_2025.08.21.671206v1.39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704201"},{"key":"2025082810202021000_2025.08.21.671206v1.40","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1200\/JCO.1993.11.2.294","article-title":"Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias","volume":"11","year":"1993","journal-title":"J Clin Oncol"},{"key":"2025082810202021000_2025.08.21.671206v1.41","first-page":"402","article-title":"Phase I trial of yttrium-90-HuM195 in myeloid leukemia potential for myeloablation","volume":"15","year":"2000","journal-title":"Cancer Biother Radiopharm"},{"key":"2025082810202021000_2025.08.21.671206v1.42","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.jmir.2019.05.008","article-title":"Targeted Alpha-Particle Therapy for Hematologic Malignancies","volume":"50","year":"2019","journal-title":"J Med Imaging Radiat Sci"},{"key":"2025082810202021000_2025.08.21.671206v1.43","first-page":"1935","article-title":"Pharmacokinetics and Dosimetry of an \u03b1-Particle Emitter Labeled Antibody: 213Bi-HuM195 (Anti-CD33) in Patients with Leukemia","volume":"40","year":"1999","journal-title":"Journal of Nuclear Medicine"},{"key":"2025082810202021000_2025.08.21.671206v1.44","doi-asserted-by":"crossref","unstructured":"J. G. Jurcic , T. L. Rosenblat , Targeted Alpha-Particle Immunotherapy for Acute Myeloid Leukemia. Am Soc Clin Oncol Educ Book, e126\u2013e131 (2014).","DOI":"10.14694\/EdBook_AM.2014.34.e126"},{"key":"2025082810202021000_2025.08.21.671206v1.45","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.39"},{"key":"2025082810202021000_2025.08.21.671206v1.46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001239"},{"key":"2025082810202021000_2025.08.21.671206v1.47","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41557-020-00598-7","article-title":"Developing the 134Ce and 134La pair as companion positron emission tomography diagnostic isotopes for 225Ac and 227Th radiotherapeutics","volume":"13","year":"2021","journal-title":"Nature chemistry"},{"key":"2025082810202021000_2025.08.21.671206v1.48","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.jmir.2019.03.037","article-title":"Thorium-229 Generator Production of Actinium-225 at Oak Ridge National Laboratory","volume":"50","year":"2019","journal-title":"Journal of Medical Imaging and Radiation Sciences"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.08.21.671206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:24:43Z","timestamp":1768469083000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.08.21.671206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":48,"URL":"https:\/\/doi.org\/10.1101\/2025.08.21.671206","relation":{},"subject":[],"published":{"date-parts":[[2025,8,25]]},"subtype":"preprint"}}